Published in J Am Soc Nephrol on December 03, 2008
Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics (2009) 1.18
Molecular diagnostics in transplantation. Nat Rev Nephrol (2010) 1.01
The urine proteome for radiation biodosimetry: effect of total body vs. local kidney irradiation. Health Phys (2010) 0.97
Application of systems biology principles to protein biomarker discovery: urinary exosomal proteome in renal transplantation. Proteomics Clin Appl (2012) 0.93
Urinary proteomics as a novel tool for biomarker discovery in kidney diseases. J Zhejiang Univ Sci B (2010) 0.93
Proteomics and metabolomics in renal transplantation-quo vadis? Transpl Int (2012) 0.85
Application of proteomic analysis to the study of renal diseases. Nat Rev Nephrol (2009) 0.82
Proteomic profiling of renal allograft rejection in serum using magnetic bead-based sample fractionation and MALDI-TOF MS. Clin Exp Med (2010) 0.81
Immunologic monitoring in transplantation revisited. Curr Opin Organ Transplant (2012) 0.81
The nephrologist of tomorrow: towards a kidney-omic future. Pediatr Nephrol (2016) 0.81
Recent advances in biomarker discovery in solid organ transplant by proteomics. Expert Rev Proteomics (2011) 0.78
Noninvasive methods to assess the risk of kidney transplant rejection. Expert Rev Clin Immunol (2009) 0.78
The Use of Genomics and Pathway Analysis in Our Understanding and Prediction of Clinical Renal Transplant Injury. Transplantation (2016) 0.77
Urinary Biomarkers of Brain Diseases. Genomics Proteomics Bioinformatics (2016) 0.77
Proteomic portrayal of transplant pathologies. J Am Soc Nephrol (2009) 0.77
Proteomics for rejection diagnosis in renal transplant patients: Where are we now? World J Transplant (2016) 0.76
Significance of urinary proteome pattern in renal allograft recipients. J Transplant (2014) 0.75
High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI). Proteomes (2013) 0.75
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
TM4: a free, open-source system for microarray data management and analysis. Biotechniques (2003) 38.02
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem (1993) 27.24
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med (1999) 15.69
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Anal Chem (1991) 5.62
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
A study of the quality of life and cost-utility of renal transplantation. Kidney Int (1996) 4.51
Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet (2003) 4.01
Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res (2004) 2.41
Long-term survival in renal transplant recipients with graft function. Kidney Int (2000) 2.38
Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant (2005) 1.79
Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J Am Soc Nephrol (2003) 1.77
Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis (2003) 1.70
Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol (2004) 1.67
Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg (2003) 1.54
Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant (2002) 1.33
A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst (2007) 1.30
Effect of histological damage on long-term kidney transplant outcome. Transplantation (2001) 1.24
Chronic allograft nephropathy: An update. Kidney Int (1999) 1.19
Protocol biopsies in renal transplantation: prognostic value of structural monitoring. Kidney Int (2007) 1.17
Urinary proteome of steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome of childhood. Am J Nephrol (2006) 1.14
Patient survival following renal transplant failure in Canada. Am J Transplant (2005) 1.10
Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant (2007) 1.10
Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant (2004) 1.06
Early protocol renal allograft biopsies and graft outcome. Kidney Int (1997) 1.02
Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations. Kidney Int Suppl (2005) 0.99
Sample preparation and bioinformatics in MALDI profiling of urinary proteins. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.92
Mining mass spectra for diagnosis and biomarker discovery of cerebral accidents. Proteomics (2004) 0.88
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol (2013) 2.62
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33
Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat Cell Biol (2013) 2.20
Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology (2003) 2.01
Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 1.93
A systematic approach to managing pregnant dialysis patients--the importance of an intensified haemodiafiltration protocol. Nephrol Dial Transplant (2005) 1.87
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs (2007) 1.76
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation (2011) 1.66
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl (2004) 1.65
Endoscopic ultrasonography-guided brushing increases cellular diagnosis of pancreatic cysts: A prospective study. Dig Liver Dis (2010) 1.58
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. Nephron Clin Pract (2003) 1.46
Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant (2012) 1.45
Gene expression profiling identifies molecular pathways associated with collagen VI deficiency and provides novel therapeutic targets. PLoS One (2013) 1.44
[A 50-year-old woman with pulmonary infiltrates]. Med Clin (Barc) (2008) 1.39
Influence of the ionic dialysance monitor on Kt measurement in hemodialysis. Am J Kidney Dis (2008) 1.39
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation (2004) 1.39
Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol (2012) 1.37
The biliverdin chromophore binds covalently to a conserved cysteine residue in the N-terminus of Agrobacterium phytochrome Agp1. Biochemistry (2004) 1.34
Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation. Eur Radiol (2004) 1.31
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
Characterization of the human plasma phosphoproteome using linear ion trap mass spectrometry and multiple search engines. J Proteome Res (2010) 1.20
Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics (2009) 1.18
The structure and dynamics of DNA in the gas phase. J Am Chem Soc (2003) 1.13
Endoscopic ultrasound-guided fine needle aspiration: predictive factors of accurate diagnosis and cost-minimization analysis of on-site pathologist. Gastroenterol Hepatol (2007) 1.12
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol (2004) 1.12
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant (2004) 1.12
Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant (2002) 1.11
Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol (2007) 1.10
CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse. J Immunol (2005) 1.10
Light-induced conformational changes of cyanobacterial phytochrome Cph1 probed by limited proteolysis and autophosphorylation. Biochemistry (2005) 1.09
Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis (2006) 1.09
Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol (2010) 1.07
Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment. J Proteome Res (2008) 1.07
Feasibility of transvaginal natural orifice transluminal endoscopic surgery-assisted living donor nephrectomy: is kidney vaginal delivery the approach of the future? Eur Urol (2011) 1.05
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant (2004) 1.05
Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. Atherosclerosis (2004) 1.05
Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther (2011) 1.04
Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol (2007) 1.03
Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol (2003) 1.02
Knowledge management for systems biology a general and visually driven framework applied to translational medicine. BMC Syst Biol (2011) 1.01
Theoretical study of the truncated hemoglobin HbN: exploring the molecular basis of the NO detoxification mechanism. J Am Chem Soc (2005) 0.99
Pregnancy on intensified hemodialysis: fetal surveillance and perinatal outcome. Fetal Diagn Ther (2007) 0.99
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int (2008) 0.97
Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant (2005) 0.96
Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol (2003) 0.96
Generation of induced pluripotent stem cells from human renal proximal tubular cells with only two transcription factors, OCT4 and SOX2. J Biol Chem (2012) 0.93
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia (2012) 0.93
Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin Chem Lab Med (2011) 0.93
Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography- guided fine-needle aspiration biopsy. Clin Cancer Res (2004) 0.93
Electrospray ionization mass spectrometry of oligosaccharides derived from fucoidan of Ascophyllum nodosum. Carbohydr Res (2007) 0.93
Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumour Biol (2011) 0.91
mTOR inhibition: the learning curve in kidney transplantation. Transpl Int (2010) 0.91
Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. Clin Cancer Res (2004) 0.91
Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother (2004) 0.91
Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant (2004) 0.90
The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation (2007) 0.90
First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol (2016) 0.90
Tubular and interstitial expression of ICAM-1 as a marker of renal injury in IgA nephropathy. Am J Nephrol (2003) 0.89
Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int (2009) 0.88
Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology (2012) 0.88
Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation (2008) 0.88
Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(®)) in renal transplant recipients. Nephrol Dial Transplant (2011) 0.88
Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant (2005) 0.88
Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site? J Med Chem (2003) 0.87
Integration of DIGE and bioinformatics analyses reveals a role of the antiobesity agent tungstate in redox and energy homeostasis pathways in brown adipose tissue. Mol Cell Proteomics (2007) 0.87
Sympathetic dystrophy associated with sirolimus therapy. Transplantation (2008) 0.87
Renal transplantation in HIV-infected patients: 2010 update. Kidney Int (2011) 0.86
Sirolimus-associated testicular toxicity: detrimental but reversible. Transplantation (2012) 0.86
mTOR inhibition and erythropoiesis: microcytosis or anaemia? Nephrol Dial Transplant (2011) 0.86
p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol (2003) 0.86
Nocturnal, every-other-day, online haemodiafiltration: an effective therapeutic alternative. Nephrol Dial Transplant (2011) 0.86
Skeletal muscle mitochondrial function is preserved in young patients with chronic renal failure. Am J Kidney Dis (2002) 0.86
Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction. Transplantation (2009) 0.85
Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation (2004) 0.85
KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma. J Immunol (2014) 0.85
Renal dysfunction in the setting of HIV/AIDS. Curr HIV/AIDS Rep (2012) 0.84
Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant (2007) 0.84
Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int Suppl (2008) 0.84
Weekly risedronate in kidney transplant patients with osteopenia. Transpl Int (2007) 0.84
Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem (2003) 0.84
Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation (2004) 0.83